Time to next treatment and survival analysis. (A) TTNT calculated on each treatment received (it includes also patients who received rituximab more than once). (B) Progression-free survival determined on 33 patients from the initiation of the (first) treatment with rituximab to the date of progression, death, or last follow-up. (C) Overall survival determined on 33 patients from the initiation of the (first) treatment with rituximab to the date of death or last follow-up.